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ABSTRACT
Alzheimer’s disease (AD), slowly continuous neurological disorder, mostly appears in older >65 age that deals with the memory loss due to death or 
damage of brain cells and cognitive functions (thinking, reasoning, and behavior abnormalities) due to the accumulation of the specific protein (beta-
amyloid protein) which form plaque and fibers (tau tangles) in the brain. Not only the genetic factors are responsible but also most of the non-genetic 
factors are responsible for AD. Several mutations in the gene (APP, APOE, PENS1, PENS2 on chromosome no. 21, 19, 14, 1) are responsible for causing 
four types of AD. Memory loss is most common sign of AD. Predisposing factors of AD are hereditary, severe brain injury or traumatic, and metabolic 
diseases such as diabetes mellitus, hypercholesteremia, and obesity. Although treatment can manage some symptoms in few people, but there is no 
current mechanism to cure AD or stop its progression. Beta-secretase inhibitor molecule prevents the first step in a chain accumulation which leads 
to the formation of amyloid plaque in the brain. However, the scientist or researchers have established a compound NIC5-15 they have been found 
NIC5-15 has safe and effectual treatment which has been used to stabilize cognitive performance in patients with mild to moderate AD.
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INTRODUCTION
Alzheimer’s disease (AD) is a slowly progressive neurological 
disorder which is deals with the death of brain cells causes’ memory 
loss and by disturbances in reasoning, planning, and languages, 
perception, and ultimately patient’s premature death [1]. AD is one 
of the basic causes of dementia that affects the 1 of 8 persons older 
than 65 years of age [2]. The prevalence of AD noted that out of 1000 
persons which lying between age 65 and 69 have been increased 
around 2.8%, similarly out of 1000 persons age about 90 years have 
56.1% incidence (49). World widely, more than 11 million people are 
goes though Alzheimer disease. At present, it is still not cure [2-3]. 
If the condition remains incurable, the expected estimation become 
doubled, and around 80 million people will be affected in the upcoming 
years [4]. A postmortem performed on AD patient’s brains revealed 
as neuropathological appearance, the existence of senile plaques 
and neurofibrillary tangles, described by beta-amyloid peptides and 
hugely phosphorylated tau protein [5]. Aggregation and deposition 
of beta-amyloid protein and abnormally phosphorylated tau protein 
(neurofibrillary tangles) in the brain lead the development of AD. 
Three major enzymes (α-, β-, and-γ secretases) are responsible for 
degradation in amyloid precursor peptide (APP) and a shortcoming 
between the clearance and production of Aβ40-42 fragments by the 
enzymes β- and γ-secretases margins to the accretion of Aβ peptide 
monomers, oligomers and finally the Aβ plaques that botch or bungle 
the parenchymal space between neurons in the brain [6]. Till exact 
cause of these various changes is undiscovered, but the progress age, 
and genetic factors and non-genetic factors perform an important 
role. Mutations in the gene APP gene on chromosome No. 21, ApoE 
on chromosome No. 19, presenilin 1 on chromosome No. 14, and 
presenilin 2 on chromosome No. 1 are associated with AD [7].
EPIDEMIOLOGY
According to the study conducted in Baston, Framingham, Rochester, 
and Baltimore the age-specific incidence rate of AD is doubled in 
every 5 years after the age of 60 and increased from about 0.17% per 
year at age 65, to 0.7% per year at age 75, 1.0% per year at age 80 %, 
and 2.92% per year at age 85 [8]. The epidemiology of the disease 
estimated in 2001 was around 24 million globally and predict that if 
condition remains incurable, the estimation becomes double in every 
20 years, and around 80 million people will be affected by 2040. The 
percentage of patients will rise from 80% to 190% from 2001 to 
2014 in Europe and the advanced western Pacific region. However, 
more than 300% were seen in Latin America, India, China, and the 
Middle Eastern crescent. The rate of incidence is approximately 2% 
in 65-69 years of age, 25% in people aged over 90 years. According 
to the study, it is more estimated in females than males because of 
the greater life expectation of female. At present, 5.3 million people 
are estimated in the United State and 5.1 million of people aged over 
65 years [9].
PATHOPHYSIOLOGY
The pathophysiology of the AD is associated with brain injury and 
death of neurons in the brain region which leads to the effects on 
memory and learning, and then alter the whole brain. In the past 
several years, Abeta plaques and neurofibrilly tangles are the two 
identified hallmarks in the brain of this disorder. Abeta plaque is 
accumulated in the extracellular space in the brain and its initiating 
lesion formation in the brain and that ultimately leads to AD while the 
neurofibrillary tangles accumulated intracellular part and presence 
of tangles appears essential to dementia. Synapse loss, neuron loss, 
and cerebral atrophy are other pathological features. In AD, there is 
abnormally deposition of tau protein (t-protein), components of the 
cytoskeleton microtubule system becomes hyperphosphorylated 
and aggregates as paired helical filament leads to deposition of 
neurofibrillary tangles in the nerve cells. According to the current 
information, changes in cerebrospinal fluid (CSF) levels of abeta, 
tau, and phosphorylated tau (P-tau). The exact mechanism of the 
formation of plaque and neurofibrillary tangles are still unknown. 
The neuron death and injury are prompted by the neurofibrillary 
tangles and senile plaque, which lead to the behavioral symptomatic 
changes and memory loss. Senile plaques are not alone neurotoxic, 
but the α-β-oligomers which are circulating potentially neurotoxic. 
The uncontrolled release of glutamate (neurotransmitter) contributes 
to inflammation and neuronal death. Neuroinflammation is also 
involved in the pathology of the AD as well the symptoms [10].
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CLINICAL MANIFESTATION
The clinical manifestation of AD is divided into three groups [11].
a. Contemporary lack of ability to remember, depression, clement 
coordination problems, and apathy.
b. Because of memory loss that disrupts daily life activity, such as person 
is unable to perform a regular task and also problems with language, 
disorientation to time and places.
c. Executive dysfunction such as poor judgment, mood swing and 
behavior, problems with abstruse thinking, misplacement in 
things, slowly changes in personality, and severe loss of ability to 
remember [12].
RISK FACTORS
Age-related changes in the brain; mostly in people who are older than 
65 years of age develop AD [13]. The main risk factor is increasing the 
age. On the basis of the population of ages the frequency of the AD is 
continuously increasing after 65 years of age [14].
On other hand some risk factors for AD include persistent high blood 
pressure (hypertension), heart disease (coronary artery disease), 
diabetes, smoking, obesity, dyslipidemia, body weight, and traumatic 
brain injury also have an increased prospects for AD [15].
Genetics of AD - mutation in APP gene on chromosome No. 21, 
presenilin-1 on chromosome No. 14, presenilin-2 on chromosome 
No. 1, ApoE -ε4 gene is the dominant risk factor that conceals a protein 
which is involved for the metabolism of cholesterol. ApoE exists three 
alleles: ε2, ε3, and ε4. ApoE-ε3 allele is mostly rich in the population, 
and ApoE-ε4 is responsible for increasing the risk of AD [16,17], and it 
is also responsible for deposition of Aβ plaque in the brain a majority 
of patients with Down syndrome will have high chances to develop the 
brain changes of AD [18,19].
The other risk factors for the AD are aluminum. Aluminum (Al) 
is a routinely type of metal are found in the environment, and in 
the terrestrial crust most abundantly it is also used. By natural 
process such as soil erosion and volcanic eruptions it is liberated 
in the environment [20]. Nowadays, developing countries are 
widely using aluminum utensils [21]. The foodstuff particularly 
salty, acidic and alkaline may have been observed with a high level 
of aluminum content [22]. Aluminum (Al) is also used in food 
additives and toothpaste [23]. Intake of excess Al leads to memory 
impairments [24], amyloid protein deposition in central nerve cells 
(CNS) and overexpression of APP [25]. Researchers and scientist 
showed that excess intake of Al cause neurotoxicity which is associated 
with apoptosis [26-27] and oxidative stress [28-29].
BIOCHEMICAL BIOMARKER
Amyloid beta
Amyloid precursor protein is abundantly used for the production of 
36-43 amino acid, which comprises the amyloid beta. 1, 14, 15, 16 and 
37, 38, 34, 40, 42 are the isoforms of amyloid beta. The discovered 
function of amyloid beta is protection against oxidative stress [30], 
enzymes such as JNK and MAPK are activated [31], and also seen 
effect in improvement of synaptic plasticity and memory [32] and 
it has functions to show the activity against microorganism [33]. 
Neurotoxicity causes when oligomers (ligand binding complexes) 
attacked at specific synapses [34]. In AD patient the levels of Aβ-42 in 
the CSF are decreased. The calculated ratio of Aβ-42/Aβ-40 is useful for 
the untimely and clinical phases of (AD) ,and other isoforms ratio also 
calculated and found 14, 15, 16, 37, 38 and 39 isoforms are useful [35]. 
During the determination, the difference in an AD from non-AD showed 
that Aβ1-42 IS 79% and specificity is 61% [36]. On familial AD the Aβ-
42 levels are increased in plasma. Aβ42-Aβ40 ratio is less present in the 
CSF of the non-demented mutation carriers (MCs) [37].
CSF-Tau
Tau protein is necessary to the study of factors that promotes the 
microtubule formation. In the middle of 1970s, it was discovered 
first by Weingarten et al. [38]. CSF tau protein, components of the 
cytoskeleton microtubules system and is concealed by a single gene 
based on chromosome no. 17q21 [39]. Microtubule-associated protein 
that is CSF-tau suggest acute injury successively development of plaque, 
but in case of vascular dementia more amount of CSF-tau is found that 
arise in a lower specificity. During the full course of AD, high CSF-tau 
is present which results in dementia [40]. For segregating the AD 
patient with Frontotemporal dementia, tau is also found helpful [41]. 
Two isoforms of tau protein, total tau, and P-tau, elevation of these two 
consider sensitive indications of presymptomatic disease [42].
IMAGING AND RADIOLOGICAL MARKER
Investigation of the AD can be possible alone through autopsy after death, 
and examine the brain tissue. Accumulation of Aβ plaque in the brain 
is the useful biomarker for the estimation of the AD and such kind of 
clinical changes in brain are estimated by various tools such as positron 
emission computed tomography (PET) or single photon emission 
computed tomography. Two other tools are magnetic resonance imaging 
(MRI), and computer aided tomography is also useful for visualization 
of the brain tissue which helps for the diagnosis of AD. In AD patients, 
extensive contraction of the brain region is observed which is involved in 
memory process. These observations are helpful for discriminating the 
progress from normal to MCI and from MCI to AD [43]. The metabolic 
activity of the brain is another diagnostic parameter consistent in AD. 
In the early stage of AD patient determine the decreased level of brain 
metabolism due to the brain atrophy and neuronal loss [44]. PET scans 
with fluorodeoxyglucose (FDGPET) and functional MRI (FMRI) are 
useful for the demonstration of metabolic activity of the brain [45,46]. 
FMRI is helpful for measuring the difference in oxygen concentration 
associated to cortical blood flow, and FDGPET is responsible for 
measuring glucose metabolism in the brain region populations. 11C-PIB 
(Pittsburgh compound B) is the advanced diagnostic tool for the AD. 
According to the study 11C-PIB load is the indicator of the progression 
of the disease in the next 2 years [47,48].
INFLAMMATORY MARKERS
Due to the deposition of amyloid plaque in the brain cytokine 
interleukin (IL)-6, C-reactive protein, interleukin IL-1-beta, tumor 
necrosis factor-α, IL-6, IL-6 receptor complex, α-antichymotrypsin, 
and transforming growth factor-β, these inflammatory markers have 
been express in the CSF of AD patient and these CSF components 
are not able to differentiate the AD patients and non-AD demented 
patient [49]. These inflammatory mediators are released in AD. Due to 
the inflammation, several proteins are detected using enzyme-linked 
immunosorbent assay in previous studies. During inflammation in the 
AD the cytokine study are produced, and it shows various results such 
as CSF interleukin-6 levels are elevated, decreased, or unchanged in 
AD [50].
GENETIC MARKERS
There are five main genes responsible for causing AD; these are APP, 
PSEN 1, PSEN 2, APOE, and TOMM40.
Mutation in the gene APP, PSEN 1, and PSEN 2 are responsible for early 
onset of AD and APOE is the only gene which is responsible for early-
onset disease [51].
Molecular diagnostic test: Mutation screening is surely theoretically 
achievable, mostly by focusing with decreasing cost of genomic DNA 
analysis. Although there is no way to determine that which children 
have AD because currently, predictive screening is not present due to 
on phenotyping it show sporadic nature [52].
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APP
APP gene located on chromosome No. 21 concealed a transmembrane 
protein named APP, consists of 39-43 amino acids arrangement 
comparable to the Aβ peptide. The degradation of Aβ peptide produced 
from APP by β and λ secretases. Aβ peptide being the major component 
of amyloid plaque accumulation in the brain region. Single nucleotide 
mutation of 24 APP is reported as causes AD, and these mutations 
are gathered with 54 amino acid sections, bounded close to the Aβ 
peptides. The Swedish mutation leads to the interchange of 2 amino 
acids lysine - methionine to asparagine - leucine before the initiation 
of Aβ peptide sequence. Production of Aβ peptide is much higher than 
that it was produced from the non-mutated APP, thus declining the 
efficacy of β-secretase cleavage. Besides another, APP mutation occurs 
after the C-terminal amino acids of Aβ peptides, thus changing the 
activity of λ- secretase cleavage. Normal APP proteolysis occurred by 
λ- secretase leads the formation Aβ40 with smaller amounts of Aβ that 
are Aβ42 [53].
PSEN1 and PSEN2
Mutation of the Presenilin 1 on chromosome No. 14 and Presenilin 2 
on chromosome No. 1. these two genes concealed the two firmly linked 
proteins which are a part of λ-secretase complex. When the mutation 
occurs on these two genes, it leads the alteration in the λ-secretase [54].
APOE gene
ApoE gene being the only prominent genetic biomarker for the late 
onset of the AD has been found to be situated on chromosome No. 19. 
It encodes for ApoE which is one of the components of lipoprotein. 
ApoE is in turn divided into three allelic forms, namely, ε2, ε3, and ε4. 
All the three ApoE polymorphs ε2, ε3, and ε4 are strongly bound with 
the AD. ApoE has a vital role in lipid metabolism along with CNS. Since 
ApoE, is the major cholesterol lipoprotein transporter, thus possess a 
magnanimous role in cholesterol transportation and brain integrity 
maintenance because lipids are important for axons myelinations. 
But it has been found that ε4 ApoE allele suppresses the cholesterol 
delivery and therefore depressing the lipid homeostasis in the CNS and 
leading to Aβ accumulation [55].
Treatment
AD is an incurable disease. The aim of treatment is to control the 
sign and symptoms such as loss of memory, behavior problems, and 
cognition, and sleep problems.
Drug treatment
The Food and Drug Administration permitted that five drugs for AD cure 
such as donepezil, rivastigmine, galantamine, tacrine, and memantine, 
these drugs are used to slow down the rate of symptoms before they 
become worsen.
Treatment of behavioral symptoms
For depression, antidepressant drugs such as clomipramine and 
placebo are given to the patient for 6 weeks [56,57].
As the AD progresses, there is a constant decrease in the stages of 
rapid eye movement and non-rapid eye movement causing the patient 
to remain awake for too long [58], tacrine and metrifonate and the 
cholinergic agonist xanomeline these drugs are helpful for reducing the 
hallucinations than those persons who take a placebo [59].
CONCLUSION
AD is a progressive neurological disorder that leads the death of brain 
cells causes’ memory loss and disturbance in reasoning, listening, 
planning, and learning. Mostly older peoples are affected (>65 age). 
Not only the genetic factors are responsible for causing, but also 
environmental factors are also responsible. The exact cause is still 
not known, but the sign and symptoms can control by drug treatment. 
The diagnosis of AD can be possible particularly through autopsy 
after death, by combining clinical measures with an examination of 
brain tissue. Some diagnostic tools are helpful for the diagnosis such 
as computerized scan, MRI, and positron emission tomography. These 
tools distinguish the AD from other causes of memory loss. Patients 
should be in undertaken with strictly care.
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